Based on the fact that p300/CBP is an important co-transcriptional activator regulating the expression of a wide range of pro-oxidant, pro-inflammatory, and pro-fibrotic genes, we postulate that pharmacological targeting of p300/CBP could become a promising supportive therapeutic option in DKD. The gene discussed is EP300; the disease is diabetic kidney disease.